Welcome to our dedicated page for Processa Pharmaceuticals SEC filings (Ticker: PCSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Processa Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Processa Pharmaceuticals's regulatory disclosures and financial reporting.
Processa Pharmaceuticals (PCSA) – Form 4 Insider Filing
On 24 Jul 2025, Chief Executive Officer & Director George K. Ng received 1,822,471 Restricted Stock Units (RSUs) under the 2019 Omnibus Incentive Plan at a $0 exercise price. Each RSU converts into one common share as follows: one-third vests on 1 Jan 2026 and the remainder vests monthly through 1 Jan 2028. Footnote 1 states that 1,859,318 of the underlying shares are contingent on stockholder approval of a revised plan.
After the grant, Ng beneficially owns 1,922,471 derivative securities linked to PCSA common stock, all held directly. No open-market purchases or sales were reported; the transaction reflects an equity-based compensation award that could add up to roughly 1.8 million new shares to the float once vested and, where applicable, approved.